Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic ObesityGlobeNewsWire • 08/20/25
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 08/05/25
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/25
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025GlobeNewsWire • 07/22/25
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025GlobeNewsWire • 07/12/25
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity MarketSeeking Alpha • 07/10/25
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study DataZacks Investment Research • 07/10/25
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?Zacks Investment Research • 07/10/25
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 07/10/25
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockGlobeNewsWire • 07/09/25
Rhythm Pharma Surges To Record High On 'Impressive' Results In ObesityInvestors Business Daily • 07/09/25
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityGlobeNewsWire • 07/09/25
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic ObesityGlobeNewsWire • 07/08/25
Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent ProspectsSeeking Alpha • 06/30/25
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025GlobeNewsWire • 06/25/25
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramGlobeNewsWire • 05/14/25
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/25
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 05/07/25
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 04/30/25